145 related articles for article (PubMed ID: 1985703)
1. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes.
Basta M; Fries LF; Frank MM
Blood; 1991 Jan; 77(2):376-80. PubMed ID: 1985703
[TBL] [Abstract][Full Text] [Related]
2. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
3. High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway.
Basta M; Fries LF; Frank MM
Blood; 1991 Aug; 78(3):700-2. PubMed ID: 1859883
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.
Basta M; Kirshbom P; Frank MM; Fries LF
J Clin Invest; 1989 Dec; 84(6):1974-81. PubMed ID: 2687331
[TBL] [Abstract][Full Text] [Related]
5. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance.
Basta M; Langlois PF; Marques M; Frank MM; Fries LF
Blood; 1989 Jul; 74(1):326-33. PubMed ID: 2752117
[TBL] [Abstract][Full Text] [Related]
6. Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro.
Brown EJ; Joiner KA; Frank MM
J Clin Invest; 1983 Jun; 71(6):1710-9. PubMed ID: 6863540
[TBL] [Abstract][Full Text] [Related]
7. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes.
Miletic VD; Hester CG; Frank MM
J Immunol; 1996 Jan; 156(2):749-57. PubMed ID: 8543829
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of immune precipitation by complement.
Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
[TBL] [Abstract][Full Text] [Related]
9. Receptors on guinea-pig erythrocytes specific for cell-bound fourth component of human complement (C4).
Wilson AB; Prichard-Thomas S; Lachmann PJ; Coombs RR
Immunology; 1980 Feb; 39(2):195-202. PubMed ID: 7380467
[TBL] [Abstract][Full Text] [Related]
10. Alternative complement pathway activation by C4b deposited during classical pathway activation.
Matsushita M; Okada H
J Immunol; 1986 Apr; 136(8):2994-8. PubMed ID: 2937839
[TBL] [Abstract][Full Text] [Related]
11. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum.
Schreiber AD; Frank MM
J Clin Invest; 1972 Mar; 51(3):583-9. PubMed ID: 4622104
[TBL] [Abstract][Full Text] [Related]
12. Intravenous and standard immune serum globulin preparations interfere with uptake of 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity.
Berger M; Rosenkranz P; Brown CY
Clin Immunol Immunopathol; 1985 Feb; 34(2):227-36. PubMed ID: 4038476
[TBL] [Abstract][Full Text] [Related]
13. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites.
Schreiber AD; Frank MM
J Clin Invest; 1972 Mar; 51(3):575-82. PubMed ID: 4536807
[TBL] [Abstract][Full Text] [Related]
14. High dose intravenous immunoglobulin does not affect complement-bacteria interactions.
Wagner E; Platt JL; Frank MM
J Immunol; 1998 Feb; 160(4):1936-43. PubMed ID: 9469456
[TBL] [Abstract][Full Text] [Related]
15. IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model.
Wagner E; Platt JL; Howell DN; Marsh HC; Frank MM
J Immunol; 1999 Sep; 163(6):3549-58. PubMed ID: 10477630
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometry based detection of HLA alloantibody mediated classical complement activation.
Wahrmann M; Exner M; Regele H; Derfler K; Körmöczi GF; Lhotta K; Zlabinger GJ; Böhmig GA
J Immunol Methods; 2003 Apr; 275(1-2):149-60. PubMed ID: 12667679
[TBL] [Abstract][Full Text] [Related]
17. High-dose intravenous immunoglobulin treatment activates complement in vivo.
Mollnes TE; Høgåsen K; De Carolis C; Vaquero E; Nielsen EW; Fontana L; Perricone R
Scand J Immunol; 1998 Sep; 48(3):312-7. PubMed ID: 9743219
[TBL] [Abstract][Full Text] [Related]
18. A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia.
Brown EJ; Hosea SW; Hammer CH; Burch CG; Frank MM
J Clin Invest; 1982 Jan; 69(1):85-98. PubMed ID: 7054244
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.
Wada J; Shintani N; Kikutani K; Nakae T; Yamauchi T; Takechi K
Clin Exp Immunol; 2001 May; 124(2):282-9. PubMed ID: 11422206
[TBL] [Abstract][Full Text] [Related]
20. Complement C3 deposition onto bacteria by neonatal serum is not enhanced after the infusion of intravenous immunoglobulin.
Lassiter HA; Speranza MJ; Hall RT; Meade V; Christensen RD; Parker CJ
J Perinatol; 1990 Mar; 10(1):27-31. PubMed ID: 2107285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
